CD274 and head and neck squamous cell carcinoma: Considering the findings in the Keynote-048 study, Pembrolizumab was approved as a first-line agent alone or in combination with Cisplatin or 5-Fu in HNSCC patients with unresectable PD-L1 combined positive score (CPS) ≥ 1 [10,20].